There is a significant need to improve endocrine therapy to address the deficiencies in current modalities in terms of (i) accounting for the effects of all estrogens, (ii) targeting all cancer-involved estrogen receptors, and (iii) accounting for antagonizing one estrogen receptor target while unwittingly agonizing the another. Here, ESR1 is linked to cancer.